<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19738" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Color Vision</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naifeh</surname>
            <given-names>Jeffrey</given-names>
          </name>
          <aff>Arkansas College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaufman</surname>
            <given-names>Evan J.</given-names>
          </name>
          <aff>University of Virginia Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Naifeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Evan Kaufman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19738.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The surface of the human retina contains about 6 million cones and 100 million rods. Cones transmit color information; rods focus on greater sensitivity to low-light conditions. The fovea is the retina's center, predominately concentrated with cones to accommodate high visual acuity in high-light conditions. Photon-powered isomerization of rhodopsin, a complex consisting of vitamin-A-derived retinal and the protein opsin, is the molecular mechanism of action for retina cells (photoreceptors).<xref ref-type="bibr" rid="article-19738.r1">[1]</xref><xref ref-type="bibr" rid="article-19738.r2">[2]</xref><xref ref-type="bibr" rid="article-19738.r3">[3]</xref></p>
      </sec>
      <sec id="article-19738.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Within rhodopsin, light absorption leads to a chemical reaction that forces part of the rhodopsin molecule to translocate by&#x000a0;changing protein conformation and exposing active sites. This activated form of rhodopsin is known as metarhodopsin. MetarhodopsinII activates many copies of the G protein transducin (by replacing transducin's GDP with GTP). Activated transducin complexes and activated cyclic nucleotide phosphodiesterase (PDE) can hydrolyze 1000 molecules of cGMP to 5'-GMP per second. cGMP-gated channels in the plasma membrane of these rods (or cones) allow sodium ion influx at high cGMP concentrations; this&#x000a0;is balanced by cation exchanger-mediated glutamate efflux, maintaining cell depolarization (dark conditions). At low cGMP concentrations, these channels close, stopping sodium ion influx and reducing glutamate efflux, leading to cell hyperpolarization (light conditions). Thus, light-induced rod/cone state changes lead to hyperpolarization of the photoreceptor cells,&#x000a0;which&#x000a0;cease to transmit&#x000a0;the neurotransmitter glutamate. Conversely, photoreceptor cells without the presence of light exist in the&#x000a0;depolarized state and continuously&#x000a0;release glutamate.</p>
        <p>The light response is a one-to-one effect. The enzyme rhodopsin kinase quickly binds metarhodopsin II, phosphorylating and halting its activity. The protein arrestin binds phosphorylated metarhodopsin II. Innate GTPase activity in transducin eventually degrades bound GTP to GDP, leading to PDE dissociation and inactivation. MetarhodopsinII is unstable and splits within minutes, leading to opsin and free trans-retinal. Trans-retinal is transported&#x000a0;to pigment epithelial cells that convert trans-retinal back to 11-cis-retinal, which eventually is recombined with opsin within cones/rods to reform rhodopsin. Guanylate cyclase restores cGMP concentration, and the cone/receptor is ready to respond to another light exposure event.</p>
        <p>Additionally, phototransduction is subject to regulation by a calcium-mediated pathway to quickly diffuse a large gradient response, such as sudden flashes of light in the dark. In dark conditions, intracellular calcium levels are high due to calcium diffusion through cGMP-gated channels. Lack of frequent light response allows more calcium to enter the cell per second due to high intracellular cGMP concentrations. Calcium ion binding to rhodopsin kinase increases the rate of rhodopsin phosphorylation, reducing transducin activation. Calcium ion binding to guanylate cyclase accelerates the restoration of cGMP concentration. Calcium ion binding to calmodulin increases cGMP affinity to its gated channel.&#x000a0;</p>
        <p>Color vision results from the combination of signals from&#x000a0;3 visual pigment types within cones: red, green, and blue, corresponding to cone types L, M, and S (RGB-LMS). Those colors correspond to the wavelengths of peak light absorption intensities&#x000a0;of the modified chromophores. L cones have peak absorptions at 555 nm to 565 nm, M cones at 530 nm to 537 nm, and S cones at 415 nm to 430 nm.&#x000a0;This color vision arises from the shifted cones' peak absorption levels and, ultimately, the brain's interpretation of the composition of these points of wavelength absorption. The entire pathway is sometimes referred to as the retinoid cycle.<xref ref-type="bibr" rid="article-19738.r4">[4]</xref><xref ref-type="bibr" rid="article-19738.r5">[5]</xref><xref ref-type="bibr" rid="article-19738.r6">[6]</xref><xref ref-type="bibr" rid="article-19738.r3">[3]</xref></p>
      </sec>
      <sec id="article-19738.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Improper Color Vision Recognition/Color Blindness</bold>
</p>
        <p>Many forms of color vision recognition abnormalities are present in the population, with most having a genetic origin (congenital). Very few individuals are color blind but instead see a disrupted range of colors. The most common forms are protanopia and deuteranopia, conditions arising from the loss of function of&#x000a0;1 of the cones, leading to dichromic vision. Protanopia is the loss of L cones (red), resulting in only green-blue vision. Deuteranopia is the loss of M cones (green), resulting in red-blue vision only. Both are X-linked alleles, therefore almost exclusively occurring in males, occurring with a prevalence of 1%. Loss of S cones rarely occurs in 0.01% of males and females. In these cases,&#x000a0;1 of the cones is not expressed, and physically, in its place,&#x000a0;1 of the others is expressed. Similar to above, but not as severe in its symptoms, is the condition anomalous trichromatic vision (tritanomaly), where all 3&#x000a0;cones are present, but the color vision is aberrant. The&#x000a0;2 common forms, protanomaly and deuteranomaly, result in L or M cones being replaced with a cone of intermediate spectral tuning. Both are X-linked and occur in 7% of males.<xref ref-type="bibr" rid="article-19738.r7">[7]</xref></p>
        <p>
<bold>Non-Color Vision Associated Diseases Affecting the Cones</bold>
</p>
        <p>In addition to disorders of proper color recognition,&#x000a0;many vision diseases display phototransduction defects affecting&#x000a0;many portions of the signal pathway and its regulation. Here, color vision function is lessened, and scotopic (low-light, rod-associated) vision is also lessened.</p>
        <p>
<bold>Stationary Night Blindness (CSNB)</bold>
</p>
        <p>One such disease is congenital stationary night blindness. It is a&#x000a0;genetic defect resulting in functional cones but dysfunctional rods.&#x000a0;Many potential culprits have been identified for this disease, including abnormal rhodopsin, arrestin, rod transducin, rod phosphodiesterase, and rhodopsin kinase. Studies have demonstrated that in some populations of this disease, rods are stuck permanently, outputting light signals.&#x000a0;There are currently no treatments for this disorder. In CSNB, b-waves are reduced (in CSNB type 2) or absent (in CSNB type 1) during an electroretinogram.</p>
        <p>
<bold>Retinitis Pigmentosa (RP)</bold>
</p>
        <p>Another disease affecting rod function is retinitis pigmentosa, a progressive retina degeneration leading to blindness of&#x000a0;genetic origins. Frequently, it begins in the early phase as night blindness and eventually progresses to loss of vision of&#x000a0;mid-periphery leading to the center, manifesting as tunnel vision. These clinical manifestations are associated with faulty rod functioning; if cones begin to be affected, then blindness eventually results. RP is characterized by reduced or absent A-waves and B-waves during an electroretinogram. It has a prevalence of 1 in 3500 individuals.</p>
        <p>
<bold>Malnutrition-Associated</bold>
</p>
        <p>Deficiency in the essential nutrient vitamin A leads to night blindness and, through the deterioration of the receptor outer segments, can eventually lead to permanent blindness.</p>
        <p>
<bold>Experimental Therapies</bold>
</p>
        <p>Currently, there are no FDA-approved treatments for CSNB or RP. However, there is the promise of gene therapy interventions on the horizon. The recent completion of several phase I/II clinical trials of retinal gene therapies utilizing adeno-associated virus has shown moderate success in preventing disease onset and progression for several years following treatment. Knowledge of specific abnormal phototransduction genes for a given disease is key to even minimal treatment.<xref ref-type="bibr" rid="article-19738.r3">[3]</xref></p>
        <p>
<bold>Common Reversible Causes</bold>
</p>
        <p><bold>Alcoholism</bold> has been associated with worsened scores on color blindness aptitude tests, case reports of which improved during and after hospital stays.<xref ref-type="bibr" rid="article-19738.r8">[8]</xref></p>
        <p><bold>Ethambutol Toxicity</bold> (TB treatment) can result in severe red-green color blindness. Full-color vision usually returns several months after stopping the drug.<xref ref-type="bibr" rid="article-19738.r9">[9]</xref></p>
        <p><bold>Phenytoin Toxicity</bold> has been reported to cause a long-standing but reversible loss of color vision. Typically, normal acuity does not return until about a year after discontinuing the drug.<xref ref-type="bibr" rid="article-19738.r10">[10]</xref></p>
        <p><bold>PDE5 Inhibitors</bold> such as <bold>sildenafil</bold> and <bold>tadalafil</bold> have been reported to cause transient loss of color vision rarely. This is thought to be due to cross-reactivity to the PDE6 in retinal photoreceptors. In a case report, full-color acuity, as demonstrated by Isahara plate tests, returned 1-week post-administration.<xref ref-type="bibr" rid="article-19738.r11">[11]</xref></p>
        <p><bold>Obstructive jaundice</bold> can cause transient loss of color vision, which returns once the underlying jaundice is corrected. It is thought that the elevated bilirubin is the mechanism involved.<xref ref-type="bibr" rid="article-19738.r12">[12]</xref></p>
        <p>Poorly-controlled <bold>Systemic lupus erythematosus (SLE)</bold> can lead to chiasmal disease (optic neuritis), which manifests as temporal hemifield defects, decreased visual acuity as gaged by a Snellen test, and variable loss of color vision ability. Full return to baseline acuity is common with aggressive treatment of the SLE.<xref ref-type="bibr" rid="article-19738.r13">[13]</xref></p>
        <p>Acute occupational exposure to <bold>toluene</bold> causes reversible loss of color vision in about 25 percent of people, specifically confusion in the blue-yellow spectrum. Return to baseline typically occurs 3 days after the last exposure.<xref ref-type="bibr" rid="article-19738.r14">[14]</xref></p>
      </sec>
      <sec id="article-19738.s4" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Color blindness is a group of eye disorders that affect the perception of color. The most common color vision deficiency is a red-green color vision. Affected individuals often have difficulty differentiating between yellow, red, and green shades. Blue-yellow color vision defects are rare. Color vision problems can also be due to medications, chemical exposure, and old age. Once diagnosed, there is no cure for inherited color deficiency, but those related to medications, injury, or illness can be improved. Thus, besides the ophthalmologist, the nurse and pharmacist must know color vision defects and their causes. Any drug known to affect color vision should be discontinued. The patient should be referred to the ophthalmologist or optometrist for specially designed eyeglasses or red-tinted contact lenses.<xref ref-type="bibr" rid="article-19738.r15">[15]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Color vision deficiency may limit jobs in certain professions, but the condition is not life-threatening. While the Occupational and Safety Health Administration neither precludes employers from requiring normal vision for essential job duties nor requires employers to maintain a color-blind, aware environment, the organization has deferred to the society standards of specific professions. For example, the standard American Society of Mechanical Engineers B30.2-2001,&#x000a0;<italic toggle="yes">Overhead, and Gantry Cranes,</italic> requires that operators of cab-operated and pulpit-operated cranes be able to distinguish between colors if such is needed for proper equipment operation.&#x000a0;The recent availability of tinted lenses and glasses has allowed most people to adapt to various deficits. Gene therapy may be available to restore vision in those with hereditary disorders of colored vision deficiency.<xref ref-type="bibr" rid="article-19738.r16">[16]</xref><xref ref-type="bibr" rid="article-19738.r17">[17]</xref><xref ref-type="bibr" rid="article-19738.r3">[3]</xref></p>
      </sec>
      <sec id="article-19738.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19738&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19738">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19738/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19738">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19738.s6">
        <title>References</title>
        <ref id="article-19738.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vagell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vagell</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baden</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>SMARTA: Automated testing apparatus for visual discrimination tasks.</article-title>
            <source>Behav Res Methods</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>2597</fpage>
            <page-range>2597-2608</page-range>
            <pub-id pub-id-type="pmid">30187437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>O'Neal</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Luther</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <chapter-title>Retinitis Pigmentosa</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">30137803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddix</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Funke</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kinney</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Irvin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kunkle</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Aircrew Low-Intensity Threat Laser Eye Protection.</article-title>
            <source>Mil Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>184</volume>
            <issue>Suppl 1</issue>
            <fpage>593</fpage>
            <page-range>593-603</page-range>
            <pub-id pub-id-type="pmid">30901431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musilov&#x000e1;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pluh&#x000e1;cek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marten-Ellis</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bedell</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Siderov</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Contour interaction under photopic and scotopic conditions.</article-title>
            <source>J Vis</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">30029215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fain</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sampath</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Rod and cone interactions in the retina.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">29899971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassall</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Barnard</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>MacLaren</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Gene Therapy for Color Blindness.</article-title>
            <source>Yale J Biol Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-551</page-range>
            <pub-id pub-id-type="pmid">29259520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marechal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delbarre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tesson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lacambre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Froussart-Maille</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Color Vision Tests in Pilots' Medical Assessments.</article-title>
            <source>Aerosp Med Hum Perform</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>737</fpage>
            <page-range>737-743</page-range>
            <pub-id pub-id-type="pmid">30020059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Layden</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Color vision defects in alcoholism. II.</article-title>
            <source>Br J Addict Alcohol Other Drugs</source>
            <year>1971</year>
            <month>Jun</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-7</page-range>
            <pub-id pub-id-type="pmid">5314808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Chaglasian</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Toxic optic neuropathy associated with ethambutol: implications for current therapy.</article-title>
            <source>J Am Optom Assoc</source>
            <year>1994</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>332</fpage>
            <page-range>332-8</page-range>
            <pub-id pub-id-type="pmid">8071504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakral</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shenoy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deleu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Acute visual dysfunction following phenytoin-induced toxicity.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>218</fpage>
            <page-range>218-20</page-range>
            <pub-id pub-id-type="pmid">15008507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kaja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Alba</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Association of Transient Colorblindness With Sildenafil and Tadalafil.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-118</page-range>
            <pub-id pub-id-type="pmid">30286227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varnek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ring-Larsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krogh</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Reversible colour vision defects in obstructive jaundice.</article-title>
            <source>Acta Ophthalmol (Copenh)</source>
            <year>1981</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-97</page-range>
            <pub-id pub-id-type="pmid">6973262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frohman</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Frieman</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wolansky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Reversible blindness resulting from optic chiasmitis secondary to systemic lupus erythematosus.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-21</page-range>
            <pub-id pub-id-type="pmid">11315975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Este</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boggess</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tavener</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Harrex</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impairment of color vision in aircraft maintenance workers.</article-title>
            <source>Int Arch Occup Environ Health</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>84</volume>
            <issue>7</issue>
            <fpage>723</fpage>
            <page-range>723-33</page-range>
            <pub-id pub-id-type="pmid">21076964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Celik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rohrschneider</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Electronic vision aids : New options for rehabilitation of the visually impaired].</article-title>
            <source>Ophthalmologe</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>115</volume>
            <issue>7</issue>
            <fpage>553</fpage>
            <page-range>553-558</page-range>
            <pub-id pub-id-type="pmid">29322255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirji</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aboshiha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Georgiou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Michaelides</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options.</article-title>
            <source>Ophthalmic Genet</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-157</page-range>
            <pub-id pub-id-type="pmid">29303385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19738.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Morral</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ciulla</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bracha</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Gene therapy for inherited retinal and optic nerve degenerations.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-49</page-range>
            <pub-id pub-id-type="pmid">29057663</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
